New vaccine combo aims to stop breast cancer return
NCT ID NCT02826434
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This early-phase study tests a cancer vaccine (PVX-410) alone or with an immunotherapy drug (durvalumab) in 22 people with stage II or III triple negative breast cancer who have completed standard treatment. The goal is to see if the vaccine is safe and can boost the immune system to help prevent the cancer from coming back. Participants must have a specific immune type (HLA-A2+).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33607, United States
-
Massachusetts general Hospital
Boston, Massachusetts, 02114, United States
-
New York University School of Medicine
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.